Civil Surgeons: Treponemal vs Nontreponemal Testing That Passes I-693

Treponemal tests detect antibodies specific to Treponema pallidum and generally remain reactive for life, confirming exposure rather than treatment response. Nontreponemal tests, including RPR and VDRL, detect antibodies against lipoidal antigens and are reported as quantitative titers used to stage disease and track therapy. Clinicians rely on both in sequence, since neither test alone tells the full story.

TL;DR:

• Nontreponemal tests like RPR and VDRL detect active disease and their titers decrease after successful treatment, while treponemal tests like TP-PA and EIA confirm past or current exposure but remain positive for life.
• The sensitivity of nontreponemal tests is about 75% in primary syphilis, with both test types reaching peak sensitivity in secondary syphilis, but late stages often show low nontreponemal titers.
• The two testing algorithms differ: traditional begins with nontreponemal screening, while reverse starts with automated treponemal screening, each with distinct advantages and false-positive risks.
• Discordant results require careful review, repeat testing, and consideration of treatment history, as false positives can occur from autoimmune conditions or pregnancy.
• For immigration exams, labs must perform all tests on the same specimen, report exact titers, and follow strict documentation rules to prevent delays and unnecessary retesting.

Table of Contents

• Serologic basis and common assays you will see on lab reports
• Timing and kinetics of serologic responses across syphilis stages
• Traditional versus reverse testing algorithms and lab reflex rules
• Interpreting concordant and discordant result patterns
• Clinical uses and monitoring: choosing the right test at the right time
• Laboratory pitfalls and specimen handling clinicians should watch for
• I-693 civil surgeon requirements and documentation checklist for syphilis testing
• Comparative sensitivity and specificity across syphilis stages
• Clinical scenarios and indications for choosing the right test
• Public health implications of screening and reporting
• Clinic perspective: workflow tips to reduce retesting and I-693 delays
• How we handle syphilis testing for your I-693 exam
• Sources
• FAQ

Serologic basis and common assays you will see on lab reports

The two test families measure fundamentally different things. Nontreponemal tests detect antibodies against cardiolipin-like lipoidal antigens released when host tissue is damaged by infection, so their titers rise and fall with disease activity. Treponemal tests detect antibodies aimed specifically at T. pallidum proteins, a response that tends to persist for decades regardless of treatment, according to CDC’s 2024 laboratory recommendations.

That distinction shapes how each result gets used. A reactive nontreponemal titer tells you something is happening now or happened recently. A reactive treponemal test tells you the person was infected at some point, treated or not, last year or twenty years ago.

On a lab report, you will typically encounter:

• RPR (rapid plasma reagin): a nontreponemal card test read visually or by automated instrument, widely used for screening and titer monitoring.
• VDRL (Venereal Disease Research Laboratory): an older nontreponemal test still used for cerebrospinal fluid testing and some titer comparisons.
• TP-PA (Treponema pallidum particle agglutination): a treponemal confirmatory test, often the preferred adjudicator when other treponemal assays give ambiguous results.
• FTA-ABS (fluorescent treponemal antibody absorption): an older treponemal test, less common now but still referenced in some algorithms.
• EIA (enzyme immunoassay): an automated treponemal screening assay used heavily in reverse-sequence testing.
• CIA (chemiluminescence immunoassay): another automated treponemal platform, functionally similar to EIA in reverse screening.

The clinical implication is straightforward once you separate the two behaviors. Nontreponemal titers move: they climb with active infection and fall (usually fourfold) after adequate therapy. Treponemal antibodies mostly do not move: once positive, a person often stays serologically positive for life, which is exactly why treponemal tests confirm exposure history rather than active disease.

Timing and kinetics of serologic responses across syphilis stages

Antibody detection does not happen instantly, and the two test types do not become reactive on the same schedule. In many patients, treponemal antibodies appear slightly before nontreponemal antibodies, though both typically lag behind the appearance of the primary chancre by one to several weeks, based on reviews of diagnostic testing patterns in peer-reviewed literature.

In primary syphilis, nontreponemal tests are approximately 75% sensitive, according to the CDC syphilis pocket guide, meaning roughly one in four early infections could be missed on RPR or VDRL alone if the window period has not yet closed. This is the practical reason clinicians consider direct detection methods such as darkfield microscopy or PCR of lesion material when a chancre is present and serology is nonreactive.

By secondary syphilis, sensitivity for both test types rises sharply, and nontreponemal titers are typically at their highest during this stage, reflecting peak disease activity. Two related concepts matter for interpretation later in the disease course:

• Serofast state: a minority of adequately treated patients retain a persistently low, stable nontreponemal titer for years without reinfection, which complicates using titers alone to judge treatment failure.
• Seroreversion: treponemal test results can occasionally revert to negative after early treatment, particularly when therapy is given during primary syphilis, though this is not the typical outcome and treponemal reactivity should generally be assumed permanent.

These kinetics explain why a single test drawn too early in the disease course, or interpreted without knowing the stage, can mislead a clinician who expects a clean positive or negative answer.

Traditional versus reverse testing algorithms and lab reflex rules

Laboratories use one of two accepted sequences to screen for syphilis, and civil surgeons completing Form I-693 need to know which one their reference lab runs because it changes what shows up on the report.

The traditional algorithm screens with a nontreponemal test (RPR or VDRL) first, then confirms any reactive specimen with a treponemal assay, typically TP-PA. The reverse algorithm screens with an automated treponemal immunoassay (EIA or CIA) first, then reflexes reactive specimens to a quantitative nontreponemal test. When the reverse screen is treponemal-positive but the nontreponemal reflex is negative, the CDC’s STI treatment guidelines call for adjudication with a second, different treponemal assay, preferably TP-PA, before the result is called positive or negative.

Each approach has tradeoffs clinicians should recognize before ordering:

• The reverse algorithm detects more infections overall, including previously treated cases, but generates more false positives, which means more patients need counseling about a positive treponemal screen that does not reflect active disease.
• The traditional algorithm’s manual RPR or VDRL card reading is slower and more labor-intensive for high-volume labs, one reason many reference labs have shifted to automated treponemal screening.
• Patients should be told upfront that a positive screening result is not automatically a diagnosis of current infection, since discordant patterns are common enough to expect rather than treat as a lab error.

For immigration medical exams specifically, the choice of algorithm is left to the civil surgeon’s laboratory, but the documentation requirements that follow are not optional, a point covered in the I-693 checklist section below.

Interpreting concordant and discordant result patterns

Once both a nontreponemal and a treponemal result exist for a patient, the real work is matching the pattern to a clinical meaning. Four combinations cover almost every case a clinician will see.

Working through a discordant result methodically avoids both overtreatment and missed disease:

1. Confirm the specimen and repeat testing before assuming a false positive, since specimen mix-ups are more common than true assay error.
2. Review the patient’s treatment history carefully, since a nontreponemal-negative, treponemal-positive pattern often simply reflects a prior, adequately treated infection.
3. Apply the fourfold titer rule when monitoring treatment response: a titer that drops from, say, 1:32 to 1:8 or lower within the expected timeframe indicates an adequate serologic response, while failure to achieve that decline suggests treatment failure or reinfection.
4. For reverse-sequence discordance (treponemal-positive, nontreponemal-negative on reflex), order a second treponemal assay, with TP-PA preferred, before finalizing the interpretation, per CDC guidance.
5. Document the exact titer value, not just “reactive” or “nonreactive,” since staging and monitoring decisions depend on the number itself.

Biological false positives on nontreponemal tests are worth naming specifically because they come up often enough to expect: other infections, autoimmune conditions, pregnancy, and recent vaccination can all trigger a reactive RPR or VDRL in someone without syphilis, according to a CDC supplemental review of clinical updates in sexually transmitted infections. This is precisely why the traditional algorithm always confirms a reactive nontreponemal screen with a treponemal test.

Clinical uses and monitoring: choosing the right test at the right time

Screening, confirmation, and monitoring call for different tools, and mixing them up wastes time and money. Nontreponemal tests do the heavy lifting for screening in many settings and are the only practical option for monitoring treatment response, since their titers actually move. Treponemal tests confirm the diagnosis and serve as a historical record of exposure, useful when a patient reports a prior infection but has no documentation.

• Order a nontreponemal test (RPR or VDRL) when screening a new patient or tracking response to therapy over time.
• Order a treponemal test (TP-PA, EIA, or CIA) to confirm a reactive nontreponemal screen or to verify a self-reported history of past infection.
• Expect nontreponemal titers to decline fourfold within 6 to 12 months after treatment for early syphilis; failure to do so signals possible treatment failure or reinfection.
• Recognize serologic relapse, a titer that rises fourfold after an initial adequate decline, as a signal to re-treat and evaluate for reinfection or neurosyphilis.
• Reserve rapid point-of-care treponemal tests for settings with limited laboratory access, since they return results in under 15 minutes but carry lower sensitivity and specificity than laboratory-based assays.

Point-of-care treponemal tests deserve a specific caution here: they are useful for same-day decisions in hard-to-reach populations, but a negative point-of-care result in a symptomatic patient should still prompt laboratory-based confirmation rather than being treated as definitive.

Laboratory pitfalls and specimen handling clinicians should watch for

A few technical quirks explain most of the “confusing” syphilis results clinicians ask about, and knowing them in advance prevents unnecessary patient recalls.

The prozone effect occurs when a very high antibody concentration interferes with the flocculation reaction on a nontreponemal test, producing a falsely nonreactive or weakly reactive result despite active, often secondary, syphilis. When clinical suspicion is high but the RPR or VDRL comes back nonreactive, request serial dilutions from the lab rather than accepting the result at face value.

RPR and VDRL titers are not interchangeable. A titer of 1:8 on RPR is not directly comparable to 1:8 on VDRL, since the two tests use different antigen preparations and flocculation conditions. Follow-up titers should be compared using the same test, and ideally the same laboratory, to avoid mistaking assay variability for a real clinical change.

Automated treponemal immunoassays report a signal-to-cutoff index rather than a simple positive or negative, and that index can vary between platforms and lots. High index values often correlate well with TP-PA confirmation, but borderline values are exactly where adjudication with a second treponemal assay matters most, a point supported by reviews of new testing algorithms.

Pro Tip: When a nontreponemal result seems inconsistent with the clinical picture, ask the lab whether dilutions were run automatically or only on request, since some labs will not catch a prozone effect unless you specifically flag high clinical suspicion.

I-693 civil surgeon requirements and documentation checklist for syphilis testing

Form I-693 has its own rules layered on top of ordinary clinical practice, and missing them is a common source of Requests for Evidence. Every civil surgeon performing an immigration medical exam needs to build these into the standard workflow.

• All required syphilis testing must be ordered and drawn at the civil surgeon exam itself; results from a test performed elsewhere, even recently, are not acceptable for Form I-693.
• Both the nontreponemal and treponemal components, when both are required by the algorithm used, must come from the same blood specimen, according to CDC’s technical instructions for civil surgeons.
• Any reactive nontreponemal test must be reported with its quantitative titer, not just as “reactive,” since Form I-693 has a specific field for the titer value.
• When a reverse algorithm produces a discordant result, a repeat treponemal test using a different assay is required, and the worksheet must reflect that repeat test was performed.
• Record the exact assay name and, where possible, the manufacturer on the worksheet, which avoids ambiguity if USCIS or a reviewing officer questions which test was actually run, a practice detailed in the complete guide to immigration lab tests.

Applicants preparing for their exam can reduce delays by understanding what documentation the civil surgeon will need in advance, covered in this guide to completing Form I-693 Part 1 before the visit. The single most common avoidable error is a nontreponemal result reported without a titer, since that omission alone can trigger a request for repeat testing weeks after the original visit.

Comparative sensitivity and specificity across syphilis stages

Neither test type performs uniformly across the disease course, and the gap between them is widest early. In primary syphilis, nontreponemal sensitivity runs around 75%, meaning a nonreactive RPR does not rule out early infection when a chancre is present, per the CDC syphilis pocket guide. Treponemal tests tend to become reactive slightly earlier in many patients, which is part of the rationale behind reverse-sequence screening in high-volume labs.

By secondary syphilis, both test families reach their highest sensitivity, since antibody levels of both types peak during this stage. Specificity works in the opposite direction: nontreponemal tests are more prone to biological false positives from unrelated conditions, while treponemal tests are generally more specific to T. pallidum exposure but cannot distinguish an active infection from one treated years earlier.

Late and latent syphilis complicate the picture further. Nontreponemal titers often decline or stabilize at low levels during latency, sometimes falling below the threshold that would prompt further workup, while treponemal tests typically remain reactive indefinitely. This is why a single test type, regardless of which one, is never sufficient to stage disease accurately across the full spectrum of syphilis presentations.

Clinical scenarios and indications for choosing the right test

The choice between treponemal and nontreponemal testing depends less on which test is “better” and more on what clinical question is being asked. A patient with a genital ulcer and no prior testing history needs a screening approach sensitive enough to catch early disease, which favors either algorithm as long as reflex rules are followed correctly.

A patient reporting treatment for syphilis years ago, now needing documentation for an immigration exam or another purpose, needs a treponemal test to confirm exposure history, since a nontreponemal titer may have already declined to nonreactive. A patient being monitored for treatment response after a recent diagnosis needs serial quantitative nontreponemal titers, since treponemal status will not change even after successful therapy.

Pregnant patients and those with neurologic symptoms suggestive of neurosyphilis represent scenarios where staging accuracy matters most, and both test types, plus sometimes cerebrospinal fluid VDRL, come into play together rather than as substitutes for one another. In each of these scenarios, the underlying principle stays the same: nontreponemal tests answer “is this active or has it changed,” and treponemal tests answer “has this person ever been exposed.”

Public health implications of screening and reporting

Syphilis is a reportable condition, and the choice of testing algorithm has consequences of the individual patient. The shift toward reverse-sequence screening in many laboratories has increased overall detection, including previously treated infections that a traditional nontreponemal-first approach might miss once titers have waned, according to reviews of new syphilis testing algorithms. That higher detection rate comes with a corresponding rise in false-positive treponemal screens that require careful adjudication before being reported to public health authorities.

Accurate titer documentation matters for surveillance as much as for individual care, since public health programs use quantitative results to track disease activity trends and monitor for treatment failure or reinfection at a population level. A screening result reported without adjudication, or a titer recorded imprecisely, can distort local case counts and complicate partner notification efforts.

For clinicians, the practical takeaway is that reporting obligations and clinical interpretation are linked: a confirmed reactive result triggers reporting regardless of whether the patient feels well, and the same documentation discipline that satisfies public health reporting also satisfies immigration exam requirements.

Clinic perspective: workflow tips to reduce retesting and I-693 delays

The biggest source of avoidable delay is not the algorithm chosen but the paperwork trailing it. Written reflex rules agreed with a reference lab, exact assay names recorded on every report, and quantitative titers present before the exam is finalized eliminate most repeat visits. Collecting all required testing on a single blood draw, then confirming titers appear on the report before completing Form I-693, catches the most common error before it becomes a Request for Evidence. Clear instructions and expedited options for patients who need faster turnaround round out a workflow built to get the form right the first time.

— ImmigrationMedicalExams Medical Team

How we handle syphilis testing for your I-693 exam

Getting the testing sequence and documentation right the first time is the difference between a straightforward I-693 exam and weeks of follow-up. We specialize exclusively in immigration medical examinations and Form I-693, with no primary care, urgent care, or sick visits diluting the focus, and we have worked exclusively in this space since 2007. Syphilis serology is performed on-site with same-sample reflex testing, and reactive nontreponemal results are reported with the quantitative titer Form I-693 requires, so nothing is missing when the form is submitted.

• We run required testing on a single blood draw, so applicants are not asked to return for a second visit.
• Standard processing takes about 3 days, with a 2-day expedited option for applicants on a tighter timeline.
• Online scheduling is available 24/7, and we frequently help applicants correct delays, errors, or incomplete documentation from exams performed elsewhere.

Our flat-package pricing is designed to avoid unexpected costs once testing is complete. If you need an exam that gets syphilis serology and the rest of Form I-693 done correctly the first time, start with our USCIS Immigration Medical Exam service page to book an appointment.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

• CDC Laboratory Recommendations for Syphilis Testing, United States, 2024
• Diagnostic tests for syphilis: New tests and new algorithms
• Form I-693 — Report of Medical Examination and Vaccination Record (USCIS)

FAQ

Which syphilis test is most accurate?

No single test is accurate across every stage of syphilis, since sensitivity and specificity shift depending on disease duration. Treponemal tests tend to become reactive earlier and stay reactive longer, while nontreponemal tests are better suited to tracking whether an infection is active, so labs use both together rather than relying on one alone.

How accurate is a syphilis test after 2 weeks?

At around 2 weeks after exposure, many patients are still within the window period where neither test type has fully seroconverted. In primary syphilis, nontreponemal tests run about 75% sensitive, so a nonreactive result this early does not rule out infection if a chancre or other symptoms are present.

What does it mean if both treponemal and nontreponemal antibodies are detected?

A positive result on both test types usually indicates an active or recent syphilis infection that has not yet been treated, or one that was treated too recently for the nontreponemal titer to have declined. The nontreponemal titer, tracked quantitatively over time, helps confirm whether the infection is responding to treatment.

What is a nontreponemal test for syphilis?

A nontreponemal test, such as RPR or VDRL, detects antibodies against lipoidal antigens released during tissue damage from infection rather than antibodies specific to the bacterium itself. These tests are reported as quantitative titers and are used for screening and for monitoring how well treatment is working, according to CDC’s 2024 laboratory recommendations.

Recommended

• Avoid Rejected Tests: U.S. I-693 Gonorrhea Testing Age 18 to 24
• Avoid I-693 Delays: 3 TB Records for Applicants With Prior TB
• Avoid I-693 Delays: U.S. Flu Vaccine Rules and 2 Day Clinic Fix
• One Dose Often Clears I-693 Vaccination for Green Card Applicants